中西医结合在慢性阻塞性肺疾病患者中的疗效观察及安全性研究

Observation on the Efficacy and Safety of Integrative Chinese and Western Medicine in Patients with Chronic Obstructive Pulmonary Disease

目的探讨中西医结合在慢性阻塞性肺疾病患者中的疗效观察及安全性。方法选择2017年5月—2018年5月入院治疗的慢性阻塞性肺疾病患者70例,根据治疗方法分为对照组(n=35例)和观察组(n=35例)。对照组采用常规西药方法治疗,观察组在对照组基础上联合自拟化痰宣肺方治疗,两组均进行1个月治疗,治疗完毕后对患者效果进行评估。采用德国power Cube肺功能仪对患者治疗前、后肺功能水平进行测定;记录并统计两组治疗后1个月恶心呕吐、腹泻、皮疹、血压升高发生率,比较两组临床疗效及安全性。结果观察组治疗后1个月FEV1水平(1.99±0.62)L、FVC(2.53±0.61)L、FEV1/FVC(63.25±6.41)%,均高于对照组FEV1水平(1.71±0.33)L、FVC(2.17±1.09)L、FEV1/FVC(54.11±5.53)%,差异有统计学意义(P<0.05)。观察组治疗后1个月恶心呕吐、腹泻、皮疹、血压升高发生率为8.57%(3/35),低于对照组5.71%(2/35),差异有统计学意义(P<0.05)。结论将中西医结合用于慢性阻塞性肺疾病患者中有助于改善患者肺功能水平,药物安全性较高,值得推广应用。

Objective To investigate the efficacy and safety of integrated Chinese and Western medicine in patients with chronic obstructive pulmonary disease. Methods A total of 70 patients with chronic obstructive pulmonary disease admitted to hospital from May 2017 to May 2018 were selected and divided into a control group(n=35) and an observation group(n=35) according to treatment methods. The control group was treated with conventional western medicine, and the observation group was combined with self-made Huayu Xuanfei Fang on the basis of the control group. Both groups were treated for one month and the efficacy of the patients was evaluated after the treatment. The use of Germany power Cube pulmonary function instrument to measure the level of lung function before and after treatment of patients;record and statistics 1 month after treatment, nausea and vomiting, diarrhea, rash, blood pressure increased the incidence of the two groups were compared clinical efficacy and safety. Results The FEV1 level(1.99±0.62)L, FVC(2.53±0.61)L, and FEV1/FVC(63.25±6.41)% in the observation group were higher than those in the control group(1.71±0.33)L at 1 month after treatment. FVC(2.17 ±1.09)L, FEV1/FVC(54.11 ±5.53)%,the difference was statistically significant(P <0.05). The incidence of nausea, vomiting, diarrhea, rash, and elevated blood pressure in the observation group was 8.57%(3/35) in the observation group, which was lower than that in the control group(5.71%(2/35),the difference was statistically significant(P<0.05). Conclusion Integrating Chinese and Western medicine in patients with chronic obstructive pulmonary disease can help improve the level of pulmonary function in patients with high drug safety and is worthy of promotion and application.